Related Experiment Video

Updated: Mar 17, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

Yong Qin1, Jason Roszik1, Chandrani Chattopadhyay1

  • 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Molecular Cancer Therapeutics
|July 27, 2016
PubMed

Insights

Hypoxia causes BRAF(V600E) melanoma cells to resist vemurafenib treatment. Upregulated HGF/MET signaling drives this resistance, which can be overcome by inhibiting the c-Met/Akt pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Melanoma exhibits significant molecular and structural heterogeneity.
  • Tumor cells within melanomas can experience hypoxic conditions.
  • BRAF(V600E) mutations are common in melanoma and targeted by vemurafenib.

Purpose of the Study:

  • To investigate the mechanisms of vemurafenib resistance in melanoma under hypoxic conditions.
  • To identify key signaling pathways involved in hypoxia-induced drug resistance.
  • To evaluate therapeutic strategies to overcome vemurafenib resistance.

Main Methods:

  • Utilized three-dimensional (3D) spheroid and two-dimensional (2D) hypoxic culture systems to model in vivo hypoxia.
  • Performed cell growth assays to assess drug sensitivity.
  • Analyzed HGF/MET signaling pathway activation in cell cultures, patient tissues, and xenografts.
  • Investigated the effect of c-Met/Akt pathway inhibition on drug sensitivity.

Main Results:

  • BRAF(V600E) melanoma cells rapidly developed vemurafenib resistance under controlled hypoxic conditions.
  • Upregulation of HGF/MET signaling was identified as a primary mechanism of resistance in hypoxia compared to normoxic conditions.
  • Increased HGF/MET signaling was observed in drug-resistant melanoma patient tissues and mouse xenografts.
  • Pharmacologic inhibition of the c-Met/Akt pathway restored vemurafenib sensitivity in hypoxic melanoma models.

Conclusions:

  • Hypoxia promotes rapid vemurafenib resistance in BRAF(V600E) melanoma.
  • HGF/MET signaling is a critical mediator of hypoxia-induced vemurafenib resistance.
  • Targeting the c-Met/Akt pathway represents a potential therapeutic strategy to overcome vemurafenib resistance in melanoma patients experiencing hypoxia.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K